{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:41:08Z","timestamp":1790710868680,"version":"4.1.0"},"reference-count":71,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>The Rho-kinase\/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.<\/jats:p>","DOI":"10.1136\/bjophthalmol-2017-310378","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T01:00:27Z","timestamp":1502326827000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["ROCK inhibitors for the treatment of ocular diseases"],"prefix":"10.1136","volume":"102","author":[{"given":"Ramin","family":"Nourinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souska","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sare","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hafezi-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"2020050712593731000_102.1.1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2476"},{"key":"2020050712593731000_102.1.1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1128"},{"key":"2020050712593731000_102.1.1.3","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721030-00004"},{"key":"2020050712593731000_102.1.1.4","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0762"},{"key":"2020050712593731000_102.1.1.5","first-page":"1727","article-title":"A selective inhibitor of the rho kinase pathway, Y-27632, and its influence on wound healing in the corneal stroma","volume":"18","author":"Yamamoto","year":"2012","journal-title":"Mol Vis"},{"key":"2020050712593731000_102.1.1.6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15681"},{"key":"2020050712593731000_102.1.1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-007-0358-7"},{"key":"2020050712593731000_102.1.1.8","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.24.8467-8477.2002"},{"key":"2020050712593731000_102.1.1.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.21.020604.150721"},{"key":"2020050712593731000_102.1.1.10","first-page":"688","article-title":"Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice","volume":"21","author":"Zeng","year":"2015","journal-title":"Mol Vis"},{"key":"2020050712593731000_102.1.1.11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.90624.2007"},{"key":"2020050712593731000_102.1.1.12","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/ICO.0000000000000493","article-title":"Inhibition of Rho-associated kinase prevents pathological wound healing and neovascularization after corneal trauma","volume":"34","author":"Sijnave","year":"2015","journal-title":"Cornea"},{"key":"2020050712593731000_102.1.1.13","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tec.2012.0429"},{"key":"2020050712593731000_102.1.1.14","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3182281ee1"},{"key":"2020050712593731000_102.1.1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.03.033"},{"key":"2020050712593731000_102.1.1.16","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12388"},{"key":"2020050712593731000_102.1.1.17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ICU.0000000000000062","article-title":"Alternatives to corneal transplantation for the management of bullous keratopathy","volume":"25","author":"Siu","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"2020050712593731000_102.1.1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.10.014"},{"key":"2020050712593731000_102.1.1.19","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1167\/iovs.15-17595","article-title":"Effect of the Rho Kinase Inhibitor Y-27632 on corneal endothelial wound healing","volume":"56","author":"Okumura","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050712593731000_102.1.1.20","doi-asserted-by":"crossref","unstructured":"Pipparelli A , Arsenijevic Y , Thuret G , et al . ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells. PLoS One 2013;8:e62095.doi:10.1371\/journal.pone.0062095","DOI":"10.1371\/journal.pone.0062095"},{"key":"2020050712593731000_102.1.1.21","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11320"},{"key":"2020050712593731000_102.1.1.22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1167\/iovs.15-18586","article-title":"Effect of the Rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing","volume":"57","author":"Okumura","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050712593731000_102.1.1.23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejps.2016.05.016","article-title":"Topical delivery of a Rho-kinase inhibitor to the cornea via mucoadhesive film","volume":"91","author":"Chan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"2020050712593731000_102.1.1.24","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.081224"},{"key":"2020050712593731000_102.1.1.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01459.x"},{"key":"2020050712593731000_102.1.1.26","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20285"},{"key":"2020050712593731000_102.1.1.27","first-page":"3455","article-title":"The mechanism of increasing outflow facility during washout in the bovine eye","volume":"43","author":"Overby","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050712593731000_102.1.1.28","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4391"},{"key":"2020050712593731000_102.1.1.29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00417-007-0666-6","article-title":"Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia","volume":"246","author":"Hirata","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050712593731000_102.1.1.30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0878"},{"key":"2020050712593731000_102.1.1.31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/bs.pbr.2015.04.014","article-title":"Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of Glaucoma filtration surgery","volume":"220","author":"Van de Velde","year":"2015","journal-title":"Prog Brain Res"},{"key":"2020050712593731000_102.1.1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.04.012"},{"key":"2020050712593731000_102.1.1.33","doi-asserted-by":"crossref","unstructured":"Pakravan M , Beni AN , Ghahari E , et al . The ocular hypotensive efficacy of topical fasudil, a Rho-Associated protein kinase inhibitor, in patients with End-Stage Glaucoma. Am J Ther 2016:1 (Epub ahead of print).doi:10.1097\/MJT.0000000000000362","DOI":"10.1097\/MJT.0000000000000362"},{"key":"2020050712593731000_102.1.1.34","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.76"},{"key":"2020050712593731000_102.1.1.35","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/aos.12641","article-title":"Efficacy and safety of SNJ-1656 in primary open-angle Glaucoma or ocular hypertension","volume":"93","author":"Inoue","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2020050712593731000_102.1.1.36","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.1038\/srep19640","article-title":"Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells","volume":"6","author":"Kaneko","year":"2016","journal-title":"Sci Rep"},{"key":"2020050712593731000_102.1.1.37","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13842"},{"key":"2020050712593731000_102.1.1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.016"},{"key":"2020050712593731000_102.1.1.39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor Ripasudil (K-115) combined with Timolol or Latanoprost: a Report of 2 Randomized Clinical Trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2020050712593731000_102.1.1.40","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle Glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"2020050712593731000_102.1.1.41","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","article-title":"Netarsudil increases outflow facility in human eyes through multiple mechanisms","volume":"57","author":"Ren","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050712593731000_102.1.1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.022"},{"key":"2020050712593731000_102.1.1.43","first-page":"395","article-title":"Rho-Associated kinase inhibitors: potential future treatments for Glaucoma","volume":"9","author":"Daneshvar","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"2020050712593731000_102.1.1.44","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00172.2004"},{"key":"2020050712593731000_102.1.1.45","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.145.6.1293"},{"key":"2020050712593731000_102.1.1.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804054105"},{"key":"2020050712593731000_102.1.1.47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaophthalmol.2013.143","article-title":"Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment","volume":"131","author":"Ahmadieh","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2020050712593731000_102.1.1.48","first-page":"337","article-title":"Intravitreal fasudil combined with Bevacizumab for treatment of refractory diabetic macular edema; a pilot study","volume":"8","author":"Nourinia","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"2020050712593731000_102.1.1.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32818-1"},{"key":"2020050712593731000_102.1.1.50","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1330"},{"key":"2020050712593731000_102.1.1.51","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0581"},{"key":"2020050712593731000_102.1.1.52","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1167\/iovs.15-17411","article-title":"Vascular normalization by ROCK inhibitor: therapeutic potential of Ripasudil (K-115) eye drop in retinal angiogenesis and hypoxia","volume":"57","author":"Yamaguchi","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050712593731000_102.1.1.53","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2011.659"},{"key":"2020050712593731000_102.1.1.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801537"},{"key":"2020050712593731000_102.1.1.55","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32832d25b3"},{"key":"2020050712593731000_102.1.1.56","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2015.01.050","article-title":"ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration","volume":"10","author":"Zandi","year":"2015","journal-title":"Cell Rep"},{"key":"2020050712593731000_102.1.1.57","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10757"},{"key":"2020050712593731000_102.1.1.58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6965"},{"key":"2020050712593731000_102.1.1.59","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1092"},{"key":"2020050712593731000_102.1.1.60","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FMJ05003X5"},{"key":"2020050712593731000_102.1.1.61","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.3892\/mmr.2015.3889","article-title":"Protection of photoreceptors by intravitreal injection of the Y-27632 Rho-associated protein kinase inhibitor in Royal College of Surgeons rats","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"key":"2020050712593731000_102.1.1.62","doi-asserted-by":"crossref","unstructured":"Wang J , Liu XH , Yang ZJ , et al . The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer 2014;14:89.doi:10.1186\/1471-2407-14-89","DOI":"10.1186\/1471-2407-14-89"},{"key":"2020050712593731000_102.1.1.63","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.brainres.2013.07.053","article-title":"RhoA activity and post-ischemic inflammation in an experimental model of adult rodent anterior ischemic optic neuropathy","volume":"1534","author":"Fard","year":"2013","journal-title":"Brain Res"},{"key":"2020050712593731000_102.1.1.64","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5265"},{"key":"2020050712593731000_102.1.1.65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12031-015-0691-6","article-title":"Fasudil, a Rho-Associated protein kinase inhibitor, attenuates traumatic retinal nerve injury in rabbits","volume":"58","author":"Yu","year":"2016","journal-title":"J Mol Neurosci"},{"key":"2020050712593731000_102.1.1.66","first-page":"652","article-title":"Rho\/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage","volume":"4","author":"Tan","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"2020050712593731000_102.1.1.67","doi-asserted-by":"crossref","first-page":"070702072507001","DOI":"10.1111\/j.1471-4159.2007.04756.x","article-title":"Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo","volume":"103","author":"Lingor","year":"2007","journal-title":"J Neurochem"},{"key":"2020050712593731000_102.1.1.68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jcph.655","article-title":"Intravitreal injection of a Rho-Kinase inhibitor (Fasudil) for recent-onset nonarteritic anterior ischemic optic neuropathy","volume":"56","author":"Sanjari","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2020050712593731000_102.1.1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.01.063"},{"key":"2020050712593731000_102.1.1.70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fncel.2014.00273","article-title":"Viral vector-mediated downregulation of RhoA increases survival and axonal regeneration of retinal ganglion cells","volume":"8","author":"Koch","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"2020050712593731000_102.1.1.71","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2012.06.037","article-title":"Erythropoietin promotes axonal regeneration after optic nerve crush in vivo by inhibition of RhoA\/ROCK signaling pathway","volume":"63","author":"Tan","year":"2012","journal-title":"Neuropharmacology"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:15Z","timestamp":1601110515000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,15]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310378"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310378","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]}}}